Associate Professor of Medicine
Mayo Clinic
Disclosure(s): Ferring Pharmaceuticals, Inc.: Grant/Research Support; Finch: Grant/Research Support; Immuron: Advisor/Consultant; Niche: Advisor/Consultant; Pfizer: Grant/Research Support; Probio Tech, LLC: Advisor/Consultant; Seres Therapeutics: Grant/Research Support; Takeda: Advisor/Consultant; Vedanta: Grant/Research Support
Dr. Sahil Khanna is a Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN. He completed Medical School at the All India Institute of Medical Sciences, New Delhi; Post Doctoral Research at University of California San Diego, CA; Residency in Internal Medicine and Fellowship in Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN before joining the Faculty. He also completed Masters in Clinical and Translational Sciences at Mayo Clinic. His interests include Epidemiology, Outcomes and Emerging Therapeutics for Clostridioides difficile infection and the interaction between C difficile and Inflammatory bowel diseases.
He has an extensive publication record with over 200 peer-reviewed publications and book chapters. He has presented all over the world in the field of C difficile infection. He has a passion for education and mentorship and serves as an associate program director for the Internal Medicine Residency Program at Mayo Clinic, Rochester, MN. He directs the C. difficile Clinic, Microbiota Therapeitcs program and the Gastroenterology inpatient servces. He has won numerous awards including the Miles and Shirley Fiterman Award, Mayo Brothers Distinguished Fellowship Award, Donald C. Balfour Mayo Clinic Alumni Association Research Award, amongst others.